-+ 0.00%
-+ 0.00%
-+ 0.00%
GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
Share
Listen to the news

Lille (France), Cambridge (Massachusetts, United States), September 9, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today highlights the long-term commercial opportunity associated with NIS4® and next-generation NIS2+®, its proprietary non-invasive NISTM diagnostic technologies aimed to identify patients with “at-risk MASH”.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending